Abstract
Introduction
The Parkinson' s disease market is approaching maturity, with the threat of
generic incursion evident in each drug class. Although growth will be stifled
by generic launches, relatively successful lifecycle management strategies and
new product launches see the Parkinson' s disease market grow at a compound
annual growth rate (CAGR) of 2.6% over the next 10 years (20082018).
Scope of this research
- In-depth analysis of the current and future Parkinson' s disease market
across the US, Japan, France, Germany, Italy, Spain and the UK.
- Parkinson' s disease-specific sales forecasts for brands and generics from
2008 to 2018.
- Assessment of the leading Parkinson' s disease brands and drug classes to
identify key success factors within this market.
- Evaluation of the strategies of leading players in the Parkinson' s disease
market.
Research and analysis highlights
Stalevo' s clear convenience and compliance benefit will see the combination
therapy emerge as the market leading brand between 2011 and 2013.
Although Boehringer Ingelheim is relatively late to the market with a
once-daily reformulation, Mirapex/Sifrol' s (pramipexole) dominant share of
some geographic markets will facilitate a successful launch in 2010.
Over the 10-year forecast period the US market will lose significance for
Parkinson' s disease market players as demographic changes and a less
competitive commercial environment will see the European and Japanese markets
emerge as key generators of growth.
Key reasons to purchase this research
- Quantify the performance of each of the marketed Parkinson' s disease drugs
in the seven major markets over the period 2008 to 2018.
- Assess the changing key opportunities and threats affecting current market
players and prospective new entrants.
- Identify the leading brands in this market over the next 10 years and
understand the key factors driving their success.
| 
View Cart
